Literature DB >> 25869997

Cholesterol, statins, and dementia: what the cardiologist should know.

Brett L Wanamaker1, Kristopher J Swiger, Roger S Blumenthal, Seth S Martin.   

Abstract

Alzheimer dementia (AD) is an important clinical problem that appears to be closely tied to comorbid cardiovascular disease, making it a relevant topic for the clinical cardiologist. Determinants of cardiovascular health, especially midlife dyslipidemia, are associated with an increased risk of dementia based on molecular and epidemiologic data. Given the potential role of dyslipidemia in the development of dementia, statins have been investigated as potential therapeutic options to slow or prevent disease. This review discusses the role of dyslipidemia and other cardiovascular risk factors in the pathogenesis of AD, with a focus on the existing evidence for the use of statin medications in the treatment and prevention of AD from observational studies and randomized clinical trials. Clinical questions for the practicing cardiologist are addressed.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25869997      PMCID: PMC4409455          DOI: 10.1002/clc.22361

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  68 in total

1.  Arterial stiffness and β-amyloid progression in nondemented elderly adults.

Authors:  Timothy M Hughes; Lewis H Kuller; Emma J M Barinas-Mitchell; Eric M McDade; William E Klunk; Ann D Cohen; Chester A Mathis; Steven T Dekosky; Julie C Price; Oscar L Lopez
Journal:  JAMA Neurol       Date:  2014-05       Impact factor: 18.302

2.  Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia.

Authors:  Minna Rusanen; Miia Kivipelto; Charles P Quesenberry; Jufen Zhou; Rachel A Whitmer
Journal:  Arch Intern Med       Date:  2010-10-25

3.  Association of Alzheimer disease pathology with abnormal lipid metabolism: the Hisayama Study.

Authors:  T Matsuzaki; K Sasaki; J Hata; Y Hirakawa; K Fujimi; T Ninomiya; S O Suzuki; S Kanba; Y Kiyohara; T Iwaki
Journal:  Neurology       Date:  2011-09-13       Impact factor: 9.910

Review 4.  Alzheimer's disease, cholesterol, and statins: the junctions of important metabolic pathways.

Authors:  Tiago Silva; José Teixeira; Fernando Remião; Fernanda Borges
Journal:  Angew Chem Int Ed Engl       Date:  2012-12-20       Impact factor: 15.336

5.  Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study.

Authors:  Kerstin Bettermann; Alice M Arnold; Jeff Williamson; Stephen Rapp; Kaycee Sink; James F Toole; Michelle C Carlson; Sevil Yasar; Steven Dekosky; Gregory L Burke
Journal:  J Stroke Cerebrovasc Dis       Date:  2011-01-14       Impact factor: 2.136

6.  Lipid lowering agents, cognitive decline, and dementia: the three-city study.

Authors:  Marie-Laure Ancelin; Isabelle Carrière; Pascale Barberger-Gateau; Sophie Auriacombe; Olivier Rouaud; Spiros Fourlanos; Claudine Berr; Anne-Marie Dupuy; Karen Ritchie
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

7.  A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.

Authors:  M Sano; K L Bell; D Galasko; J E Galvin; R G Thomas; C H van Dyck; P S Aisen
Journal:  Neurology       Date:  2011-07-27       Impact factor: 9.910

8.  Cognitive impairment and outcomes in older adult survivors of acute myocardial infarction: findings from the translational research investigating underlying disparities in acute myocardial infarction patients' health status registry.

Authors:  S Michael Gharacholou; Kimberly J Reid; Suzanne V Arnold; John Spertus; Michael W Rich; Patricia A Pellikka; Mandeep Singh; Tracey Holsinger; Harlan M Krumholz; Eric D Peterson; Karen P Alexander
Journal:  Am Heart J       Date:  2011-11       Impact factor: 4.749

9.  Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Authors:  Jennifer G Robinson; Bettina S Nedergaard; William J Rogers; Jonathan Fialkow; Joel M Neutel; David Ramstad; Ransi Somaratne; Jason C Legg; Patric Nelson; Rob Scott; Scott M Wasserman; Robert Weiss
Journal:  JAMA       Date:  2014-05-14       Impact factor: 56.272

10.  Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease.

Authors:  Yuan-Yuan Zhang; Yu-Chen Fan; Min Wang; Dong Wang; Xiao-Hong Li
Journal:  Clin Interv Aging       Date:  2013-01-31       Impact factor: 4.458

View more
  16 in total

1.  Multiple chronic conditions: Implications for cognition - Findings from the Wisconsin Registry for Alzheimer's Prevention (WRAP).

Authors:  Lisa C Bratzke; Beverly A Carlson; Chooza Moon; Roger L Brown; Rebecca L Koscik; Sterling C Johnson
Journal:  Appl Nurs Res       Date:  2018-06-18       Impact factor: 2.257

Review 2.  Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer's disease.

Authors:  Heeyoung Lee; EunYoung Kim
Journal:  Arch Pharm Res       Date:  2020-09-09       Impact factor: 4.946

Review 3.  Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease.

Authors:  Therese S Salameh; Elizabeth M Rhea; William A Banks; Angela J Hanson
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-28

4.  Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study.

Authors:  Marco Bertolotti; Carlotta Franchi; Marco B L Rocchi; Andrea Miceli; M Vittoria Libbra; Alessandro Nobili; Giulia Lancellotti; Lucia Carulli; Chiara Mussi
Journal:  Drugs Aging       Date:  2017-04       Impact factor: 3.923

5.  Statins and Brain Health: Alzheimer's Disease and Cerebrovascular Disease Biomarkers in Older Adults.

Authors:  Vijay K Ramanan; Scott A Przybelski; Jonathan Graff-Radford; Anna M Castillo; Val J Lowe; Michelle M Mielke; Rosebud O Roberts; Robert I Reid; David S Knopman; Clifford R Jack; Ronald C Petersen; Prashanthi Vemuri
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 6.  Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease.

Authors:  Akanksha Kulshreshtha; Poonam Piplani
Journal:  Neurol Sci       Date:  2016-06-01       Impact factor: 3.307

Review 7.  Current and Emerging Uses of Statins in Clinical Therapeutics: A Review.

Authors:  Jonathan T Davies; Spencer F Delfino; Chad E Feinberg; Meghan F Johnson; Veronica L Nappi; Joshua T Olinger; Anthony P Schwab; Hollie I Swanson
Journal:  Lipid Insights       Date:  2016-11-14

Review 8.  Antioxidants and Dementia Risk: Consideration through a Cerebrovascular Perspective.

Authors:  Virginie Lam; Mark Hackett; Ryusuke Takechi
Journal:  Nutrients       Date:  2016-12-20       Impact factor: 5.717

Review 9.  The Controversial Role of 24-S-Hydroxycholesterol in Alzheimer's Disease.

Authors:  Paola Gamba; Serena Giannelli; Erica Staurenghi; Gabriella Testa; Barbara Sottero; Fiorella Biasi; Giuseppe Poli; Gabriella Leonarduzzi
Journal:  Antioxidants (Basel)       Date:  2021-05-07

Review 10.  BACE1: More than just a β-secretase.

Authors:  Hannah A Taylor; Lena Przemylska; Eva M Clavane; Paul J Meakin
Journal:  Obes Rev       Date:  2022-02-04       Impact factor: 10.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.